ADC Therapeutics (ADCT) Gross Margin (2021 - 2026)
ADC Therapeutics (ADCT) posted quarterly Gross Margin of 83.37% for Q1 2026, down 768.0% year-on-year from 12.48% in Q1 2025, and down 10.05% on a QoQ basis from 92.68% in Q3 2025.
ADC Therapeutics (ADCT) Gross Margin (2021 - 2026) Analysis & Trends
ADC Therapeutics (ADCT) has reported Gross Margin for 6 consecutive years, with 83.37% the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 88.95% |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | 90.68% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 82.22% |
| 10 | ADC Therapeutics | 174.95 Mn | -56.06 Mn | 17.38 Mn | 83.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 83.37% |
| Sep 30, 2025 | 92.68% |
| Jun 30, 2025 | 95.56% |
| Mar 31, 2025 | 91.05% |
| Sep 30, 2024 | 95.39% |
| Jun 30, 2024 | 93.01% |
| Mar 31, 2024 | 86.10% |
| Sep 30, 2023 | 97.47% |
| Jun 30, 2023 | 93.16% |
| Mar 31, 2023 | 96.89% |
| Sep 30, 2022 | 98.30% |
| Jun 30, 2022 | 86.89% |
| Mar 31, 2022 | 98.86% |
| Sep 30, 2021 | 96.18% |
| Jun 30, 2021 | 96.78% |